Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,822 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,088 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03964727 | Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors(TROPiCS-03) | active not recruiting | Phase 2 | 227 | Gilead SciencesINDUSTRY | 8 | Apr 28, 2026 | clinicaltrials |
| NCT05451602 | HEC169096 in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 456 | Sunshine Lake Pharma Co., Ltd.INDUSTRY | 1 | Apr 28, 2026 | clinicaltrials |
| NCT06010342 | A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients | recruiting | Phase 2 | 60 | Teligene USINDUSTRY | 2 | Apr 28, 2026 | clinicaltrials |
| NCT06413680 | A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body(BrILliance) | recruiting | Phase 1 / Phase 2 | 240 | Regeneron PharmaceuticalsINDUSTRY | 1 | Apr 28, 2026 | clinicaltrials |
| NCT07258121 | Study of ZGGS34 in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 400 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Apr 28, 2026 | clinicaltrials |
| NCT07439094 | A First-in-Human Study of CKD-703 in Advanced Solid Tumors and Non-Small Cell Lung Cancer | recruiting | Phase 1 / Phase 2 | 140 | Chong Kun Dang PharmaceuticalINDUSTRY | 1 | Apr 27, 2026 | clinicaltrials |
| NCT03682289 | Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors | active not recruiting | Phase 2 | 83 | Rahul AggarwalOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT03810339 | Toripalimab(JS001) as Monotherapy in Participants With POLE or POLD-1 Mutated and Non-MSI-H Advanced Solid Tumors | recruiting | Phase 2 | 35 | Sun Yat-sen UniversityOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT05951608 | A Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 216 | AkesoINDUSTRY | 1 | Apr 23, 2026 | clinicaltrials |
| NCT07541001 | PRL3-Zumab in Patients With Advanced Solid Tumors(China Phase II) | active not recruiting | Phase 2 | 60 | Intra-IMMUSG Pte LtdINDUSTRY | 1 | Apr 23, 2026 | clinicaltrials |
| NCT04452955 | A Study to Assess Safety and Efficacy of PRL3-Zumab in Patients With Solid Tumors | active not recruiting | Phase 2 | 51 | Intra-IMMUSG Pte LtdINDUSTRY | 1 | Apr 22, 2026 | clinicaltrials |
| NCT07020221 | A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors | recruiting | Phase 1 / Phase 2 | 295 | Verastem, Inc.INDUSTRY | 2 | Apr 22, 2026 | clinicaltrials |
| NCT05969860 | At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer | recruiting | Phase 2 | 220 | Mayo ClinicOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT07540650 | Prophylactic Radiotherapy to Prevent Bone Complications in Patients With Metastatic Solid Cancers(pRevenT) | not yet recruiting | Phase 2 | 90 | Institute of Oncology LjubljanaOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT02713269 | Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord | active not recruiting | Phase 2 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT06777316 | A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 110 | Cogent Biosciences, Inc.INDUSTRY | 2 | Apr 17, 2026 | clinicaltrials |
| NCT04879121 | Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 2 | 13 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT07290088 | Phase II/III Trial of PRL3-Zumab in Advanced Solid Tumor Patients(PRL3-zumab) | recruiting | Phase 2 / Phase 3 | 52 | Intra-IMMUSG Pte LtdINDUSTRY | 1 | Apr 16, 2026 | clinicaltrials |
| NCT02387905 | Cement Augmentation in Preventing Vertebral Body Compression Fracture Following Spine Stereotactic Radiosurgery in Patients With Solid Tumors and Spinal Metastases | active not recruiting | Phase 2 | 87 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT04957615 | Nivolumab for the Treatment of Metastatic or Unresectable Solid Tumors With ARID1A Mutation and CXCL13 Expression | active not recruiting | Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT06799637 | Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments | recruiting | Phase 1 / Phase 2 | 350 | Evopoint Biosciences Inc.INDUSTRY | 1 | Apr 15, 2026 | clinicaltrials |
| NCT05120596 | First in Human Study of T3P-Y058-739 (T3P) | recruiting | Phase 1 / Phase 2 | 100 | T3 Pharmaceuticals AGINDUSTRY | 3 | Apr 13, 2026 | clinicaltrials |
| NCT05222620 | SRS Compared With FSRS for Treatment of Intact Metastatic Brain Disease, FRACTIONATE Trial | recruiting | Phase 2 | 90 | Mayo ClinicOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05423262 | A Study of TRK-950 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 49 | Toray Industries, IncINDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06362369 | A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy | recruiting | Phase 1 / Phase 2 | 126 | 7 Hills Pharma, LLCINDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06810544 | Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss | recruiting | Phase 1 / Phase 2 | 191 | Tango Therapeutics, Inc.INDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07326488 | A Study of MHB009C in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 200 | Minghui Pharmaceutical (Hangzhou) LtdINDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07509684 | A Phase Ib/II Study Evaluating Injectable ALK-N001 in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 190 | Zhejiang Anglikang Pharmaceutical Co., Ltd.INDUSTRY | 0 | Apr 13, 2026 | clinicaltrials |
| NCT07192107 | A Study of MHB042C in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 200 | Minghui Pharmaceutical (Hangzhou) LtdINDUSTRY | 1 | Apr 9, 2026 | clinicaltrials |
| NCT07192120 | A Study of MHB048C in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 200 | Minghui Pharmaceutical (Hangzhou) LtdINDUSTRY | 1 | Apr 9, 2026 | clinicaltrials |
| NCT06911827 | A Study of QLP2117 in Combination With QL2107 in Advanced Solid Tumor Patients | recruiting | Phase 1 / Phase 2 | 149 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 7, 2026 | clinicaltrials |
| NCT05785741 | A Study of DB-1310 in Advanced/Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 1,000 | DualityBio Inc.INDUSTRY | 2 | Apr 6, 2026 | clinicaltrials |
| NCT06306638 | Interstitial Photodynamic Therapy Following Palliative Radiotherapy in Treating Patients With Inoperable Malignant Central Airway Obstruction | recruiting | Phase 1 / Phase 2 | 42 | Roswell Park Cancer InstituteOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT07510841 | JY016 Injection in Patients With Advanced Solid Tumors Expressing EGFR | not yet recruiting | Phase 1 / Phase 2 | 228 | Biotech Pharmaceutical Co., Ltd.OTHER | 0 | Apr 6, 2026 | clinicaltrials |
| NCT03428802 | Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability | active not recruiting | Phase 2 | 21 | Rutgers, The State University of New JerseyOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT07446153 | A Clinical Study of HRS-8364 in the Treatment of Advanced Solid Tumor Subjects | recruiting | Phase 1 / Phase 2 | 282 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Apr 3, 2026 | clinicaltrials |
| NCT04665206 | Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 434 | Vivace Therapeutics, IncINDUSTRY | 2 | Apr 2, 2026 | clinicaltrials |
| NCT05735080 | Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer(INX-315-01) | recruiting | Phase 1 / Phase 2 | 150 | Incyclix BioINDUSTRY | 2 | Apr 1, 2026 | clinicaltrials |
| NCT05773820 | A Study Explore WJB001 Capsules in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 210 | Wigen Biomedicine Technology (Shanghai) Co., Ltd.INDUSTRY | 1 | Apr 1, 2026 | clinicaltrials |
| NCT03297606 | Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)(CAPTUR) | recruiting | Phase 2 | 720 | Canadian Cancer Trials GroupNETWORK | 1 | Mar 27, 2026 | clinicaltrials |
| NCT03667170 | KN035 for dMMR/MSI-H Advanced Solid Tumors | recruiting | Phase 2 | 200 | 3D Medicines (Sichuan) Co., Ltd.INDUSTRY | 1 | Mar 25, 2026 | clinicaltrials |
| NCT04891198 | ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid Tumors | recruiting | Phase 2 | 126 | 3D Medicines (Sichuan) Co., Ltd.INDUSTRY | 1 | Mar 25, 2026 | clinicaltrials |
| NCT05024214 | Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors | recruiting | Phase 1 / Phase 2 | 170 | 3D Medicines (Sichuan) Co., Ltd.INDUSTRY | 1 | Mar 25, 2026 | clinicaltrials |
| NCT06781125 | One Trial of JCXH-211 Intratumoral Injection Combined With Anti-PD-1 Antibody in Patients With Malignant Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 72 | Immorna Biotherapeutics, Inc.INDUSTRY | 0 | Mar 24, 2026 | clinicaltrials |
| NCT07222969 | A Clinical Study to Evaluate the Safety of VIB305 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 146 | Vibrant Sciences LimitedINDUSTRY | 2 | Mar 23, 2026 | clinicaltrials |
| NCT02503423 | Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas | active not recruiting | Phase 1 / Phase 2 | 253 | Taiho Oncology, Inc.INDUSTRY | 8 | Mar 20, 2026 | clinicaltrials |
| NCT07032077 | A Clinical Trial of HRS-7058 Combined Anti-tumor Drugs in Subjects With Solid Tumors | recruiting | Phase 2 | 100 | Shandong Suncadia Medicine Co., Ltd.INDUSTRY | 1 | Mar 20, 2026 | clinicaltrials |
| NCT07229638 | A IB/II Phase Clinical Study on the Safety, Tolerability, and Efficacy of SHR-9839(sc) in Combination Anti-tumor Therapy in Patients With Solid Tumors | recruiting | Phase 1 / Phase 2 | 70 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Mar 20, 2026 | clinicaltrials |
| NCT06357975 | Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1) | active not recruiting | Phase 2 | 44 | National Cancer Institute (NCI)NIH | 1 | Mar 19, 2026 | clinicaltrials |
| NCT05101070 | S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors(aCCeleR8-001) | recruiting | Phase 1 / Phase 2 | 282 | ShionogiINDUSTRY | 2 | Mar 18, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Apr 28, 2026source: clinicaltrials